Fig. 1From: Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 TrialTrial profile. HSCT hematopoietic stem cell transplantation, GVHD graft-versus-host disease, AML acute myeloid leukemia, VAH Venetoclax Combined With Azacitidine And Homoharringtonine, CRc composite complete remission, NR non-remission, PR partial remission, HD Ara-c high-dose cytarabine, OS overall survivalBack to article page